189 related articles for article (PubMed ID: 21378771)
1. VSL#3 and remission in active ulcerative colitis: larger studies required.
Jackson EL; Hamlin PJ; Ford AC
Am J Gastroenterol; 2011 Mar; 106(3):547; author reply 547-8. PubMed ID: 21378771
[No Abstract] [Full Text] [Related]
2. [Probiotics in chronic inflammatory bowel disease].
Böhm S; Kruis W
MMW Fortschr Med; 2006 Aug; 148(35-36):30-4. PubMed ID: 16995360
[TBL] [Abstract][Full Text] [Related]
3. [Ulcerative colitis. Acute episode].
Reissmann A; Bischoff SC; Fleig W
Z Gastroenterol; 2004 Sep; 42(9):994-8. PubMed ID: 15455271
[No Abstract] [Full Text] [Related]
4. [Ulcerative colitis. Complementary therapies].
Matthes H; Moser G; Jantschek G
Z Gastroenterol; 2004 Sep; 42(9):1031-2. PubMed ID: 15455282
[No Abstract] [Full Text] [Related]
5. [Maintaining remission of ulcerative colitis with the probiotic Escherichia Coli Nissle 1917 is as effective as with standard mesalazine].
Adam B; Liebregts T; Holtmann G
Z Gastroenterol; 2006 Mar; 44(3):267-9. PubMed ID: 16514573
[No Abstract] [Full Text] [Related]
6. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis.
Zocco MA; dal Verme LZ; Cremonini F; Piscaglia AC; Nista EC; Candelli M; Novi M; Rigante D; Cazzato IA; Ojetti V; Armuzzi A; Gasbarrini G; Gasbarrini A
Aliment Pharmacol Ther; 2006 Jun; 23(11):1567-74. PubMed ID: 16696804
[TBL] [Abstract][Full Text] [Related]
7. [Ulcerative colitis. Maintenance therapy].
Kruis W; Schreiber S
Z Gastroenterol; 2004 Sep; 42(9):1011-4. PubMed ID: 15455275
[No Abstract] [Full Text] [Related]
8. [News from the Cochrane Library: Maintenance of remission in ulcerative colitis].
Timmer A
Z Gastroenterol; 2007 May; 45(5):395-6. PubMed ID: 17503319
[No Abstract] [Full Text] [Related]
9. Efficacy of a symbiotic product during clinical relapse of ulcerative colitis.
Guslandi M
J Clin Gastroenterol; 2011; 45(5):475-6. PubMed ID: 21336142
[No Abstract] [Full Text] [Related]
10. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.
Tursi A; Brandimarte G; Papa A; Giglio A; Elisei W; Giorgetti GM; Forti G; Morini S; Hassan C; Pistoia MA; Modeo ME; Rodino' S; D'Amico T; Sebkova L; Sacca' N; Di Giulio E; Luzza F; Imeneo M; Larussa T; Di Rosa S; Annese V; Danese S; Gasbarrini A
Am J Gastroenterol; 2010 Oct; 105(10):2218-27. PubMed ID: 20517305
[TBL] [Abstract][Full Text] [Related]
11. Balsalazide plus high-potency probiotic preparation (VSL[sharp]3) in the treatment of acute mild-to-moderate ulcerative colitis and uncomplicated diverticulitis of the colon.
Tursi A
J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 1():S119-22. PubMed ID: 18806701
[TBL] [Abstract][Full Text] [Related]
12. [Drug therapy of inflammatory bowel diseases].
Silvennoinen J; Niemelä S
Duodecim; 1999; 115(20):2233-8. PubMed ID: 11973927
[No Abstract] [Full Text] [Related]
13. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
Lichtenstein GR; Kamm MA; Sandborn WJ; Lyne A; Joseph RE
Aliment Pharmacol Ther; 2008 Jun; 27(11):1094-102. PubMed ID: 18363894
[TBL] [Abstract][Full Text] [Related]
14. Azathioprine versus mesalamine in steroid-dependent ulcerative colitis: long-awaited results?
Cohen RD
Gastroenterology; 2006 Feb; 130(2):607-8; discussion 608. PubMed ID: 16472614
[No Abstract] [Full Text] [Related]
15. Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study.
Hyams JS; Lerer T; Mack D; Bousvaros A; Griffiths A; Rosh J; Otley A; Evans J; Stephens M; Kay M; Keljo D; Pfefferkorn M; Saeed S; Crandall W; Michail S; Kappelman MD; Grossman A; Samson C; Sudel B; Oliva-Hemker M; Leleiko N; Markowitz J;
Am J Gastroenterol; 2011 May; 106(5):981-7. PubMed ID: 21224840
[TBL] [Abstract][Full Text] [Related]
16. [Probiotics for prevention of ulcerative colitis recurrence: alternative medicine added to standard treatment?].
Folwaczny C
Z Gastroenterol; 2000 Jun; 38(6):547-50. PubMed ID: 10923365
[No Abstract] [Full Text] [Related]
17. Once-daily mesalamine (Lialda) for ulcerative colitis.
Med Lett Drugs Ther; 2007 Mar; 49(1257):25-6. PubMed ID: 17375030
[No Abstract] [Full Text] [Related]
18. Mesalamine with MMX technology for the treatment of ulcerative colitis.
Schreiber S; Kamm MA; Lichtenstein GR
Expert Rev Gastroenterol Hepatol; 2008 Jun; 2(3):299-314. PubMed ID: 19072380
[TBL] [Abstract][Full Text] [Related]
19. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.
Miele E; Pascarella F; Giannetti E; Quaglietta L; Baldassano RN; Staiano A
Am J Gastroenterol; 2009 Feb; 104(2):437-43. PubMed ID: 19174792
[TBL] [Abstract][Full Text] [Related]
20. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
Lichtenstein GR; Kamm MA; Boddu P; Gubergrits N; Lyne A; Butler T; Lees K; Joseph RE; Sandborn WJ
Clin Gastroenterol Hepatol; 2007 Jan; 5(1):95-102. PubMed ID: 17234558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
